Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Open Access is the Plan S Way Forward in Hematology Research.

Cools J, Engert A, Gribben J, Macintyre E.

Hemasphere. 2020 Jan 15;4(1):e331. doi: 10.1097/HS9.0000000000000331. eCollection 2020 Feb. No abstract available.

2.

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.

Govaerts I, Jacobs K, Vandepoel R, Cools J.

Hemasphere. 2019 Oct 22;3(6):e313. doi: 10.1097/HS9.0000000000000313. eCollection 2019 Dec. No abstract available.

3.

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia.

Verbeke D, Gielen O, Jacobs K, Boeckx N, De Keersmaecker K, Maertens J, Uyttebroeck A, Segers H, Cools J.

Hemasphere. 2019 Oct 22;3(6):e310. doi: 10.1097/HS9.0000000000000310. eCollection 2019 Dec. No abstract available.

4.

Introducing the HemaSphere Controversies Series.

Eichenauer DA, Cools J, Engert A.

Hemasphere. 2019 Sep 27;3(5):e296. doi: 10.1097/HS9.0000000000000296. eCollection 2019 Oct. No abstract available.

5.

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia.

Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.

Cancer Cell. 2020 Jan 13;37(1):135-136. doi: 10.1016/j.ccell.2019.12.010. No abstract available.

PMID:
31935370
6.

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma.

Debackere K, van der Krogt JA, Tousseyn T, Ferreiro JAF, Van Roosbroeck K, Marcelis L, Graux C, Dierickx D, Ameye G, Vandenberghe P, Michaux L, Cools J, Wlodarska I.

Blood. 2020 Feb 20;135(8):584-588. doi: 10.1182/blood.2019002401. No abstract available.

PMID:
31746983
7.

The First Year of HemaSphere and Many More to Come.

Engert A, Cools J.

Hemasphere. 2018 Nov 29;2(6):e161. doi: 10.1097/HS9.0000000000000161. eCollection 2018 Dec. No abstract available.

8.

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.

Broux M, Prieto C, Demeyer S, Vanden Bempt M, Alberti-Servera L, Lodewijckx I, Vandepoel R, Mentens N, Gielen O, Jacobs K, Geerdens E, Vicente C, de Bock CE, Cools J.

Blood. 2019 Oct 17;134(16):1323-1336. doi: 10.1182/blood.2019000015.

9.

Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells.

Kampen KR, Fancello L, Girardi T, Rinaldi G, Planque M, Sulima SO, Loayza-Puch F, Verbelen B, Vereecke S, Verbeeck J, Op de Beeck J, Royaert J, Vermeersch P, Cassiman D, Cools J, Agami R, Fiers M, Fendt SM, De Keersmaecker K.

Nat Commun. 2019 Jun 11;10(1):2542. doi: 10.1038/s41467-019-10508-2.

10.

Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.

Habets RA, de Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D, Narlawar R, Demeyer S, Dooley J, Liston A, Taghon T, Cools J, de Strooper B.

Sci Transl Med. 2019 May 29;11(494). pii: eaau6246. doi: 10.1126/scitranslmed.aau6246.

PMID:
31142678
11.

Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Fancello L, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2019 Apr;33(4):1055-1062. doi: 10.1038/s41375-019-0424-x.

12.

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.

Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, Roca-Ho H, Blanch-Lombarte O, González-García S, Torrebadell M, Junca J, Ramírez-Orellana M, Velasco-Hernández T, Bueno C, Fuster JL, Prado JG, Calvo J, Uzan B, Cools J, Camos M, Pflumio F, Toribio ML, Menéndez P.

Blood. 2019 May 23;133(21):2291-2304. doi: 10.1182/blood-2018-10-882944. Epub 2019 Feb 22.

13.

T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.

de Bock CE, Down M, Baidya K, Sweron B, Boyd AW, Fiers M, Burns GF, Molloy TJ, Lock RB, Soulier J, Taghon T, Van Vlierberghe P, Cools J, Holst J, Thorne RF.

Haematologica. 2019 May;104(5):e204-e207. doi: 10.3324/haematol.2018.198424. Epub 2018 Dec 4. No abstract available.

14.

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.

Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Baldazzi C, Guadagnuolo V, Manfrini M, Ferrari A, Paolini S, Papayannidis C, Marconi G, Franchini E, Zuffa E, Laginestra MA, Zanotti F, Astolfi A, Iacobucci I, Bernardi S, Sazzini M, Ficarra E, Hernandez JM, Vandenberghe P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haferlach T, Castellani G, Remondini D, Martinelli G.

Cancer. 2019 Mar 1;125(5):712-725. doi: 10.1002/cncr.31837. Epub 2018 Nov 27.

15.

The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells.

Brajic A, Franckaert D, Burton O, Bornschein S, Calvanese AL, Demeyer S, Cools J, Dooley J, Schlenner S, Liston A.

Front Immunol. 2018 Sep 25;9:1989. doi: 10.3389/fimmu.2018.01989. eCollection 2018.

16.

JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia.

de Bock CE, Cools J.

Mol Cell Oncol. 2018 Apr 4;5(3):e1458014. doi: 10.1080/23723556.2018.1458014. eCollection 2018.

17.

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Dec;32(12):2731. doi: 10.1038/s41375-018-0241-7.

PMID:
30232463
18.

The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models.

Vicente C, Stirparo R, Demeyer S, de Bock CE, Gielen O, Atkins M, Yan J, Halder G, Hassan BA, Cools J.

J Hematol Oncol. 2018 Aug 25;11(1):108. doi: 10.1186/s13045-018-0650-0.

19.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, Vandepoel R, Geerdens E, Radaelli E, Bornhauser BC, Kulozik AE, Meijerink JP, Bourquin JP, de Bock CE, Cools J.

Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.

20.

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Baens M, Stirparo R, Lampi Y, Verbeke D, Vandepoel R, Cools J, Marynen P, de Bock CE, Bornschein S.

Eur J Immunol. 2018 Oct;48(10):1728-1738. doi: 10.1002/eji.201847597. Epub 2018 Aug 7.

21.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Cobos FA, Bornschein S, de Bock CE, Atak ZK, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Dec;103(12):e585-e589. doi: 10.3324/haematol.2018.190587. Epub 2018 Jun 28. No abstract available.

22.

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2019 Feb;33(2):319-332. doi: 10.1038/s41375-018-0176-z. Epub 2018 Jun 21. Erratum in: Leukemia. 2019 Apr;33(4):1055-1062.

23.

Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.

De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M, De Keersmaecker K, Michaux L, Vandenberghe P, Voet T, Boeckx N, Uyttebroeck A, Cools J.

Leukemia. 2018 Jun;32(6):1358-1369. doi: 10.1038/s41375-018-0127-8. Epub 2018 Apr 18.

24.

A Micropatterned Multielectrode Shell for 3D Spatiotemporal Recording from Live Cells.

Cools J, Jin Q, Yoon E, Alba Burbano D, Luo Z, Cuypers D, Callewaert G, Braeken D, Gracias DH.

Adv Sci (Weinh). 2018 Jan 4;5(4):1700731. doi: 10.1002/advs.201700731. eCollection 2018 Apr.

25.

BCR-ABL1 positive B-ALL can undergo T-cell lineage shift to become CD19 negative T-ALL.

De Bie J, Demeyer S, Gielen O, Segers H, Michaux L, Vandenberghe P, Boeckx N, Uyttebroeck A, Cools J.

Hemasphere. 2018 Apr 19;2(3):e42. doi: 10.1097/HS9.0000000000000042. eCollection 2018 Jun. No abstract available.

26.

EML1-ABL1 Is Activated by Coiled-Coil-Mediated Oligomerization and Induces T-Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model.

Vanden Bempt M, Mentens N, Vandenberghe P, Cools J, De Keersmaecker K.

Hemasphere. 2018 Mar 6;2(2):e32. doi: 10.1097/HS9.0000000000000032. eCollection 2018 Mar-Apr.

27.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.

28.

In memory of Tessa Holyoake and Her Work on Chronic Myeloid Leukemia Stem Cells.

Cools J.

Hemasphere. 2017 Dec 20;1(1):e11. doi: 10.1097/HS9.0000000000000011. eCollection 2017 Dec. Review. No abstract available.

29.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.

30.

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Bornschein S, Demeyer S, Stirparo R, Gielen O, Vicente C, Geerdens E, Ghesquière B, Aerts S, Cools J, de Bock CE.

Leukemia. 2018 Apr;32(4):941-951. doi: 10.1038/leu.2017.328. Epub 2017 Nov 20.

31.

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Erratum in: Leukemia. 2018 Dec;32(12):2731.

32.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.

33.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

van der Krogt JA, Bempt MV, Ferreiro JF, Mentens N, Jacobs K, Pluys U, Doms K, Geerdens E, Uyttebroeck A, Pierre P, Michaux L, Devos T, Vandenberghe P, Tousseyn T, Cools J, Wlodarska I.

Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.

34.

Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.

Przybyl J, Kowalewska M, Quattrone A, Dewaele B, Vanspauwen V, Varma S, Vennam S, Newman AM, Swierniak M, Bakuła-Zalewska E, Siedlecki JA, Bidzinski M, Cools J, van de Rijn M, Debiec-Rychter M.

JCI Insight. 2017 Jun 2;2(11). pii: 94033. doi: 10.1172/jci.insight.94033. eCollection 2017 Jun 2.

35.

The genetics and molecular biology of T-ALL.

Girardi T, Vicente C, Cools J, De Keersmaecker K.

Blood. 2017 Mar 2;129(9):1113-1123. doi: 10.1182/blood-2016-10-706465. Epub 2017 Jan 23. Review.

36.

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.

Vercruysse T, De Bie J, Neggers JE, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D.

Clin Cancer Res. 2017 May 15;23(10):2528-2541. doi: 10.1158/1078-0432.CCR-16-1580. Epub 2016 Oct 25.

37.

Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.

Dagklis A, Demeyer S, De Bie J, Radaelli E, Pauwels D, Degryse S, Gielen O, Vicente C, Vandepoel R, Geerdens E, Uyttebroeck A, Boeckx N, de Bock CE, Cools J.

Blood. 2016 Dec 8;128(23):2642-2654. Epub 2016 Sep 30.

PMID:
27694322
38.

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.

Gianfelici V, Chiaretti S, Demeyer S, Di Giacomo F, Messina M, La Starza R, Peragine N, Paoloni F, Geerdens E, Pierini V, Elia L, Mancini M, De Propris MS, Apicella V, Gaidano G, Testi AM, Vitale A, Vignetti M, Mecucci C, Guarini A, Cools J, Foà R.

Haematologica. 2016 Aug;101(8):941-50. doi: 10.3324/haematol.2015.139410. Epub 2016 May 5.

39.

Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.

La Starza R, Barba G, Demeyer S, Pierini V, Di Giacomo D, Gianfelici V, Schwab C, Matteucci C, Vicente C, Cools J, Messina M, Crescenzi B, Chiaretti S, Foà R, Basso G, Harrison CJ, Mecucci C.

Haematologica. 2016 Aug;101(8):951-8. doi: 10.3324/haematol.2016.143875. Epub 2016 May 5.

40.

Generation of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing.

Vanden Bempt M, Demeyer S, Mentens N, Geerdens E, De Bock CE, Wlodarska I, Cools J.

Leukemia. 2016 Sep;30(9):1913-6. doi: 10.1038/leu.2016.62. Epub 2016 Mar 8. No abstract available.

41.

Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.

Van Roosbroeck K, Ferreiro JF, Tousseyn T, van der Krogt JA, Michaux L, Pienkowska-Grela B, Theate I, De Paepe P, Dierickx D, Doyen C, Put N, Cools J, Vandenberghe P, Wlodarska I.

Genes Chromosomes Cancer. 2016 May;55(5):428-41. doi: 10.1002/gcc.22345. Epub 2016 Feb 6.

PMID:
26850007
42.

Blood disorders stepping into the limelight.

Jäger U, Chomienne C, Cools J, Smand C.

Haematologica. 2016 Feb;101(2):101-3. doi: 10.3324/haematol.2016.142018. Epub 2016 Jan 27. No abstract available.

43.

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.

Wandinger SK, Lahortiga I, Jacobs K, Klammer M, Jordan N, Elschenbroich S, Parade M, Jacoby E, Linders JT, Brehmer D, Cools J, Daub H.

PLoS One. 2016 Jan 8;11(1):e0146100. doi: 10.1371/journal.pone.0146100. eCollection 2016.

44.

Resolutions for the New Year.

Cools J.

Haematologica. 2016 Jan;101(1):1. doi: 10.3324/haematol.2015.139352. No abstract available.

45.

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

Vicente C, Cools J.

Haematologica. 2015 Nov;100(11):1373-5. doi: 10.3324/haematol.2015.136077. No abstract available.

46.

The genomic landscape of adult T cell leukemia/lymphoma.

Vicente C, Cools J.

Nat Genet. 2015 Nov;47(11):1226-7. doi: 10.1038/ng.3428.

PMID:
26506901
47.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

48.

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.

Degryse S, Cools J.

J Hematol Oncol. 2015 Jul 26;8:91. doi: 10.1186/s13045-015-0192-7.

49.

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, La Starza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J.

Haematologica. 2015 Oct;100(10):1301-10. doi: 10.3324/haematol.2015.130179. Epub 2015 Jul 23.

50.

Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.

Durinck K, Van Loocke W, Van der Meulen J, Van de Walle I, Ongenaert M, Rondou P, Wallaert A, de Bock CE, Van Roy N, Poppe B, Cools J, Soulier J, Taghon T, Speleman F, Van Vlierberghe P.

Leukemia. 2015 Dec;29(12):2317-27. doi: 10.1038/leu.2015.162. Epub 2015 Jun 25.

PMID:
26108691

Supplemental Content

Support Center